NYSSA • The New York State Society of Anesthesiologists, Inc.
Volume 75 Number 2
Since obtaining FDA approval in 2015, the steroidal encapsulating agent sugammadex has become anesthesia providers’ neuromuscular blockade (NMB) reversal agent of choice.
You'll have to be logged in to keep reading.
Website design, development and hosting by MAjor Designs